Beijing Bethune public welfare fund Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2019
NCT04296838
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Beijing Bethune public welfare fund

Active Ingredients

Drugs in Phase 3 Trials (1)

conbercept (Lumitin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 3)

Macular Edema (Phase 3)

Uveitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1